Research programme: hydrogen sulfide-based therapeutics - Antibe Therapeutics
Alternative Names: Aspirin derivative - Antibe Therapeutics; ATB-282; ATB-284; ATB-427; ATB-428; ATB-429Latest Information Update: 03 May 2024
At a glance
- Originator Antibe Therapeutics
- Class Analgesics; Anti-inflammatories; Anticoagulants; Irritable bowel syndrome therapies; Small molecules; Sulfides; Vasodilators
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases
- No development reported Irritable bowel syndrome
Most Recent Events
- 19 Apr 2024 Hydrogen sulfide-based therapeutics is still in preclinical trials for Inflammatory bowel diseases in Canada (unspecified)
- 28 Nov 2023 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in Canada
- 29 Jun 2023 Antibe Therapeutics files for patent protection for hydrogen sulfide-based therapeutic candidate(s) for inflammatory bowel disease (IBD)